These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17581297)

  • 41. Overcoming paclitaxel resistance in lung cancer cells via dual inhibition of stathmin and Bcl-2.
    Han ZX; Wang HM; Jiang G; Du XP; Gao XY; Pei DS
    Cancer Biother Radiopharm; 2013 Jun; 28(5):398-405. PubMed ID: 23496232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2.
    Park SB; Lee JH; Jeong WW; Kim YH; Cha HJ; Joe Y; Chung HT; Cho WJ; Do JW; Lee BJ; Park JW; Ko BK
    J Chemother; 2015 Jun; 27(3):174-80. PubMed ID: 25604244
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines.
    He X; Zhang T
    Cell Biochem Biophys; 2014 Mar; 68(2):411-8. PubMed ID: 23990130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.
    Li N; Li X; Li S; Zhou S; Zhou Q
    Biochem Biophys Res Commun; 2013 Sep; 439(2):187-90. PubMed ID: 23994634
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy.
    Zheng C; Zheng M; Gong P; Deng J; Yi H; Zhang P; Zhang Y; Liu P; Ma Y; Cai L
    Biomaterials; 2013 Apr; 34(13):3431-8. PubMed ID: 23375952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fibronectin protects lung cancer cells against docetaxel-induced apoptosis by promoting Src and caspase-8 phosphorylation.
    Qin S; Zhang B; Xiao G; Sun X; Li G; Huang G; Gao X; Li X; Wang H; Yang C; Ren H
    Tumour Biol; 2016 Oct; 37(10):13509-13520. PubMed ID: 27465556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.
    Wu DW; Wu TC; Wu JY; Cheng YW; Chen YC; Lee MC; Chen CY; Lee H
    Oncogene; 2014 Aug; 33(35):4385-95. PubMed ID: 24096476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phloretin exhibits an anticancer effect and enhances the anticancer ability of cisplatin on non-small cell lung cancer cell lines by regulating expression of apoptotic pathways and matrix metalloproteinases.
    Ma L; Wang R; Nan Y; Li W; Wang Q; Jin F
    Int J Oncol; 2016 Feb; 48(2):843-53. PubMed ID: 26692364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment.
    Li Q; Yang Z; Chen M; Liu Y
    Int J Mol Med; 2016 Apr; 37(4):1067-74. PubMed ID: 26936095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Sensitivity to chemotherapeutic drugs of polyploid tumor cells induced by a spindle poison nocodazole].
    Hao J; Yuan BB; Xu YF; Yu J; Liu GY; Wang DH
    Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):419-24. PubMed ID: 22967442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells.
    Xu L; Fu Y; Li Y; Han X
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):235-242. PubMed ID: 28597042
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells.
    Rouette A; Parent S; Girouard J; Leblanc V; Asselin E
    Int J Cancer; 2012 Apr; 130(8):1755-67. PubMed ID: 21618512
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.
    Chowdhury N; Vhora I; Patel K; Doddapaneni R; Mondal A; Singh M
    Pharm Res; 2017 Nov; 34(11):2371-2384. PubMed ID: 28875330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells.
    Kumar Biswas S; Huang J; Persaud S; Basu A
    Mol Cancer Ther; 2004 Mar; 3(3):327-34. PubMed ID: 15026553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.
    Xu G; Yu H; Shi X; Sun L; Zhou Q; Zheng D; Shi H; Li N; Zhang X; Shao G
    BMC Pulm Med; 2014 Nov; 14():174. PubMed ID: 25380840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
    Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
    Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suppression of STAT3 by chemically modified siRNAs increases the chemotherapeutic sensitivity of parental and cisplatin-resistant non-small cell lung cancer cells.
    Tezcanli Kaymaz B; Bozok Cetintas V; Eroglu Z; Kosova B
    J BUON; 2014; 19(1):145-52. PubMed ID: 24659656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Knockdown of Med19 suppresses proliferation and enhances chemo-sensitivity to cisplatin in non-small cell lung cancer cells.
    Wei L; Wang XW; Sun JJ; Lv LY; Xie L; Song XR
    Asian Pac J Cancer Prev; 2015; 16(3):875-80. PubMed ID: 25735376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC.
    Ma J; Zhao Z; Wu K; Xu Z; Liu K
    Gene; 2016 Aug; 587(2):147-54. PubMed ID: 27138804
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro modulation of Bcl-2 levels in small cell lung cancer cells: effects on cell viability.
    Santos AO; Pereira JP; Pedroso de Lima MC; Simões S; Moreira JN
    Braz J Med Biol Res; 2010 Oct; 43(10):1001-9. PubMed ID: 20922271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.